Concepedia

Yingyun Wang

YW

14

Publications

1.3K

Citations

13

H-Index

2013

Active since

Affiliations

Revolution Medicines (United States)(Current)

Harvard University

Novartis (Switzerland)

Novartis (United States)

Genomics Institute of the Novartis Research Foundation

Yingyun Wang is an author at Revolution Medicines (United States) specializing in drug discovery, cancer research, and medicine.

ORCID

Top concepts

Publications per year

2013–2025

14

Publications

14

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

Matthew Holderfield, Bianca J. Lee, Jingjing Jiang et al. · Nature · 2024 · 268 citations · Full text

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato et al. · Cancer Discovery · 2024 · 231 citations · Full text

Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation

Jing Lü, Tatiana Zavorotinskaya, Yumin Dai et al. · Blood · 2013 · 161 citations · Full text

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton et al. · Nature · 2024 · 150 citations · Full text

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

Pablo D. García, John L. Langowski, Yingyun Wang et al. · Clinical Cancer Research · 2014 · 110 citations · Full text

Rows per page

1–5 of 14